Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 355.89M P/E - EPS this Y 35.30% Ern Qtrly Grth -
Income -27.92M Forward P/E - EPS next Y -126.70% 50D Avg Chg 1.00%
Sales 2M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -3.00%
Recommedations 2.00 Quick Ratio 42.95 Shares Outstanding 30.39M 52W Low Chg 9.00%
Insider Own 14.28% ROA -18.46% Shares Float 15.94M Beta -
Inst Own 76.28% ROE -26.35% Shares Shorted/Prior 2.28M/2.23M Price 16.05
Gross Margin 100.00% Profit Margin - Avg. Volume 89,276 Target Price 35.80
Oper. Margin -1,637.15% Earnings Date - Volume 57,395 Change 0.25%
About Sagimet Biosciences Inc. - Seri

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc. - Seri News
06/21/24 Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
06/10/24 Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
06/06/24 Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
05/16/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
05/15/24 Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
05/07/24 Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
05/06/24 Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
04/22/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
03/27/24 Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
06:00 AM Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
05:15 AM Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
02/29/24 Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
08:58 PM Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
01/23/24 Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
01/22/24 Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
12/04/23 Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
11/28/23 Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
11/22/23 Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
11/13/23 Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
11/10/23 Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
SGMT Chatroom

User Image valueforme Posted - 9 hours ago

$SGMT This doesn't look like usual options activity to me ..

User Image John___wick44 Posted - 13 hours ago

$SGMT mr clearly not bond sorry u dont side with the greatest to do it goldman but the peasants of the other firms who are paid hacks with outlandish and comical price targets that will never be met in the lifetime of this stock. there paid by the company to put these outlandishtargets so they can keep payikg thkeselves millions of dollars

User Image BondbutnotJames Posted - 13 hours ago

$SGMT (1 of 2) @ John_Dick Well - since you called the scumbags from Goldbärchen Sucks your friends, I want to show you what kind of scoundrels they really are. This can be seen beautifully at the following events... 01/23/2024 Buy rating - price target from $30 > $37 03/26/2024 Buy rating - price target from $37 reduced to $27 05/16/2024 Buy rating - price target from $27 reduced to $23 06/28/2024 Neutral rating - price target from $23 reduced to $6 In the same time periods, JMP Securities, SVB Leerink, HC Wainwright give price targets between $26 and $48 - apparently the three would have to be complete idiots to call for such price targets based on the research success of SGMT. Or once again it turns out that the gold bears are the biggest scoundrels active in the stock market - because who was the consortium leader of the successful capital increase? That's right - the gold bears...

User Image John___wick44 Posted - 16 hours ago

$SGMT too easy. this is about collapse to pennies after collapsing already. what a scam. insiders selling at lows because they know a RS is coming

User Image John___wick44 Posted - 17 hours ago

$SGMT two day rally highly unlikely. my pals goldman will put their foot down and smash back down

User Image insiderbuyingselling Posted - 1 day ago

$SGMT new insider selling: 8357 shares. http://insiderbuyingselling.com/?t=SGMT

User Image John___wick44 Posted - 1 day ago

$SGMT what $6 proce target r u referring to ? goldman? the one who is short a boat load of this

User Image Effe839 Posted - 1 day ago

$SGMT @John___wick44 You are litterally dominating this board with your excuse "I am shorting". Man, do you really think some messages are going to influence a stock? lol

User Image insiderbuyingselling Posted - 1 day ago

$SGMT new insider selling: 10914 shares. http://insiderbuyingselling.com/?t=SGMT

User Image ItTakesItAll Posted - 1 day ago

$SGMT quietly type still to run. $CYCC $VVOS $EZGO same type.

User Image John___wick44 Posted - 1 day ago

$SGMT scam ks going to zero rs then pemnies again

User Image John_D_Stockefeller Posted - 1 day ago

$SGMT John wick44 is very sick. Not well in the head. Keep him in your thoughts.

User Image John___wick44 Posted - 2 days ago

$SGMT nasdaq up 300 and this is down 4 peecent. market down this os down. get on the short train

User Image BiodegradableShxt Posted - 2 days ago

$SGMT Thoughts & prayers.

User Image GXD_Texas Posted - 2 days ago

$SGMT this is just a fucking straight shit show.

User Image John___wick44 Posted - 2 days ago

$SGMT last comment for day. 2.13 is all time low once we breach that it is game over.

User Image kthart Posted - 2 days ago

$SGMT buy the dip! Every day a new dip! Going going going....gone

User Image John___wick44 Posted - 2 days ago

$SGMT making 3-5 percent a day os good stuff. until tomorrow loser longs of there are any left. get on the right side of the trade. still an easy 80 perecnet to be made before RS and then we short again even harder

User Image Rggdmrkt Posted - 2 days ago

$SGMT

User Image John___wick44 Posted - 2 days ago

$SGMT listen to last conference call and u will see why mgmt is a scam. the most unprofessional call u will ever be on. thank god for the dog letting us know how kuch we shoukd sgort in this scam

User Image John___wick44 Posted - 2 days ago

$SGMT best short in the market. the gift that keeps on giving and still an easy 70 80 percent to make more here

User Image John___wick44 Posted - 2 days ago

$SGMT nice. under 3. lets go shorts put the hammer down now and send it to all time lows. we need that RS in this scam.

User Image John___wick44 Posted - 2 days ago

$SGMT scam alert. bring it under 3 for good and take it to under 2 august. mgmt is fraud and bilking u for every last dollar. look at performance somce ipo. down 80 percent and counting

User Image John___wick44 Posted - 4 days ago

$SGMT On a bright note it is only down 43 percent year to date and only $3 of downside risk until RS.

User Image John___wick44 Posted - 5 days ago

$SGMT if u dont think goldman is shorting this right with me to zero u all are living under a rock

User Image John___wick44 Posted - 5 days ago

$SGMT at what point longs will u realize this os going to pennies and a RS. is it going to be when it actually gets there. writing is on the wall where this piece of dung is going. the dog on the last call was trying to tell u in dog language the pile of cr a p this is

User Image Bionco Posted - 5 days ago

$SGMT clown show every day 🤣

User Image John___wick44 Posted - 5 days ago

$SGMT another 4 percent down in this scam. beautiful. shorts we will continue to pound this thing to where it belongs which is delisted

User Image John___wick44 Posted - 5 days ago

$SGMT this pig is about to crash and burn to under 2 real fast

User Image John___wick44 Posted - 5 days ago

$SGMT amazing not everyone is short this for a diverse portfolio. scam mgmt scam company. RS coming next year. have a nice weekend longs. thanks for the pump so i can short more

Analyst Ratings
Goldman Sachs Neutral Jul 1, 24
HC Wainwright & Co. Buy Jun 14, 24
JMP Securities Market Outperform Jun 7, 24
HC Wainwright & Co. Buy Jun 7, 24
JMP Securities Market Outperform May 24, 24
HC Wainwright & Co. Buy May 24, 24
Goldman Sachs Buy May 16, 24
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy May 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Happel David President & CEO President & CEO Nov 16 Buy 2.35 590 1,386 590 11/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Sell 16 662 10,592 3,820,275 07/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Buy 16 30,000 480,000 3,850,275 07/20/23